Back to results
US 10,702,512 B2Granted
Treatment of debilitating fatigue
AssigneeA. Carlsson Research AB
InventorsArvid Carlsson, Carl-Gerhard Gottfries
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.
Claims13
A method of treating a subject for one or more symptoms of a disorder
- characterized by debilitating fatigue, comprising:
- administering therapeutic amounts of a dopamine stabilizing agent and an anti-depressive agent to the subject, wherein the dopamine stabilizing agent is 3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine or a pharmaceutically acceptable salt thereof;
- wherein said anti-depressive agent is selected from the group consisting of escitalopram, citalopram, venlafaxine, sertraline, fluoxetine, paroxetine, duloxetine, amitriptyline, fluvoxamine, clomipramine, milnacipran, vortioxetine and vilazodone;
- wherein said disorder is selected from the group consisting of myalgic encephalomyelitis/chronic fatigue syndrome, fibromyalgia, mental fatigue, post stroke fatigue, Huntington's disease, Parkinson's disease, multiple sclerosis, narcolepsy, post cancer fatigue, fatigue associated with cancer with or without cytostatic treatment, depression, and combinations thereof;
- and
- wherein said one or more symptoms are selected from the group consisting of persistent and/or recurrent debilitating fatigue, diffuse musculoskeletal pain, sleep disturbances, neuropsychiatric symptoms, hopelessness, irritability and sadness.
3 more elements
Dependencies are inferred from the claim text.